Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision neoadjuvant immunotherapy for locally advanced driver-negative non-small cell lung cancer
ChiCTR2000035367Phase 4Completed
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Oct 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sintilimab, bevacizumab, carboplatin, paclitaxel, gemcitabine and 1 more in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: major pathologic response. Started Oct 2020; status: completed.
02
Drugs
sintilimabbevacizumabcarboplatinpaclitaxelgemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000035367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035367.